FDA Approves Subcutaneous Tremfya Induction Treatment for Ulcerative Colitis

drugs.com - 24/Sep 21:09

WEDNESDAY, Sept. 24, 2025 -- The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the...

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

drugs.com - 02/Oct 21:28

THURSDAY, Oct. 2, 2025 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active...

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

wn.com - 07:27

THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque...

FDA Approves Inluriyo for Advanced Breast Cancer

drugs.com - 30/Sep 22:09

TUESDAY, Sept. 30, 2025 -- The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the...

FDA Approves Palsonify (paltusotine) for the Treatment of Acromegaly in Adults

drugs.com - 25/Sep 19:09

SAN DIEGO – September 25, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration...

FDA Approves Palsonify (paltusotine) for the Treatment of Acromegaly in Adults

drugs.com - 25/Sep 19:09

SAN DIEGO – September 25, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration...

FDA Approves Bondlido (lidocaine topical system) for the Treatment of Post-Herpetic Neuralgia

drugs.com - 25/Sep 19:09

September 25, 2025 -- MEDRx announced that the U.S. Food and Drug Administration (FDA) has approved Bondlido, a lidocaine*1 patch MEDRx Group and D....

FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

drugs.com - 25/Sep 20:09

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...

FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

drugs.com - 25/Sep 20:09

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has...

FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria

drugs.com - 30/Sep 02:09

EAST HANOVER, N.J., Sept. 30, 2025 -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA)...

Rubriques :

FDA Approves Subcutaneous Tremfya Induction Treatment for Ulcerative Colitis

Articles similaires

FDA Approves Subcutaneous Tremfya Induction Treatment for Ulcerative Colitis

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

FDA Approves Inluriyo for Advanced Breast Cancer

FDA Approves Palsonify (paltusotine) for the Treatment of Acromegaly in Adults

FDA Approves Palsonify (paltusotine) for the Treatment of Acromegaly in Adults

FDA Approves Bondlido (lidocaine topical system) for the Treatment of Post-Herpetic Neuralgia

FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria

Les derniers communiqués